| Similar Articles |
|---|
 |
The Motley Fool
February 29, 2008
Brian Orelli |
RNAi Works -- Maybe Alnylam presents the first proof of concept that RNAi works in humans, but where's the proof that it cures a disease?   |
The Motley Fool
June 9, 2009
Brian Orelli |
Alnylam Lays Down a Sacrifice Bunt RNAi is still an unproven technology, and there's plenty of chances for it to strike out. |
The Motley Fool
November 30, 2010
Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices. |
The Motley Fool
September 24, 2010
Brian Orelli |
So Long and Thanks for All the Drug Candidates Alnylam and Novartis end their five-year partnership. |
The Motley Fool
September 20, 2007
Brian Orelli |
A Pharma Divorce, and Good Riddance Merck and Alnylam call it quits. The only real question is why the two didn't end the partnership months ago. What will it mean to investors? |
The Motley Fool
May 18, 2007
Mike Havrilla |
Ample Opportunities for Alnylam The biotech's RNAi pipeline and cutting-edge technology make it a prime takeover candidate. Investors, take note. |
The Motley Fool
February 28, 2011
Brian D. Pacampara |
Next-Generation Drug Technologies Battle It Out Alnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease. |
The Motley Fool
May 28, 2008
Brian Orelli |
A Partnership of Habitual Deal Makers A partnership between these two companies gives Alnylam another $150 million to pad its coffers with and Takeda a call option on an unproven but promising set of drugs. |
The Motley Fool
August 1, 2007
Brian Orelli |
RNAi Gets Pumped Up Is a collaboration between RNAi expert Alnylam Pharmaceuticals and medical-device maker Medtronic something investors can endorse? |
The Motley Fool
July 11, 2007
Brian Orelli |
Everybody Loves RNAi Roche is the latest firm to (over)pay for the hottest new drug technology. Alnylam announced that it licensed some of its intellectual property to Roche for $331 million. Investors, take note. |
The Motley Fool
November 6, 2006
Ralph Casale |
Validation for a Biotechnology Firm? How Merck's bid to buy a competitor could affect Alnylam Pharmaceuticals. With the recent run-up in share price due to the Merck offer for Sirna, investors should wait for a better price before speculating on Alnylam. |
The Motley Fool
March 24, 2008
Brian Orelli |
Alnylam Authorizes Again The pharmaceutical's latest patent-licensing deal won't be immediately lucrative. |
The Motley Fool
August 31, 2010
Brian Orelli |
A Mostly Meaningless FDA Rejection The Food and Drug Administration sends AstraZeneca back to the drawing board for the second time when it rejected motavizumab, the drugmaker's newest treatment for respiratory syncytial virus. |
The Motley Fool
September 28, 2007
Brian Orelli |
RNAi Doesn't Kill Mice After All From Merck, to AstraZeneca, to Novartis, big pharma continues to pump hundreds of millions of dollars into unproven RNAi technology. Investors, take note. |
The Motley Fool
October 5, 2006
Ralph Casale |
RNAi: Nobel Prize-Winning Biotechnology While drugs based on RNAi knockdown technology may have the potential to become the next big thing in biotechnology, they are still a long way from becoming FDA-approved marketable entities. But it's never too soon to start keeping an eye on the future. Investors, take note. |
The Motley Fool
November 18, 2010
Travis Hoium |
Alnylam Pharmaceuticals Shares Plunged: What You Need to Know Roche Holding AG announced it would end its partnership with Tekmira Pharmaceuticals, dragging Alnylam down in the fray. This move affects research for RNAi therapeutics, a focus for Alnylam. |
The Motley Fool
December 5, 2006
Brian Lawler |
Cubist Finds an Asian Partner The smaller drug developer teams up with AstraZeneca to bring its antibiotic to worldwide markets. The best part of the deal is that Cubist retains the rights to Cubicin in Japan, which is by far the biggest market in all of Asia. Investors, take note. |
The Motley Fool
February 9, 2006
Jason Mac Gurn |
RNA: Rule Breaker Nucleic Acid Investors, new RNA-based technologies may be the next revolution in biopharmaceuticals. ISIS Pharmaceuticals... Sirna Therapeutics... Alnylam Pharmaceuticals... |
The Motley Fool
December 1, 2008
Brian Orelli |
It's Wait Until Next Year for These Drugmakers Drugs from AstraZeneca and Eli Lilly face delays because of the FDA. Both plan to resubmit their applications for approval in the first half of next year, but the delays likely will have different effects on the companies. |
The Motley Fool
August 15, 2006
Ralph Casale |
Sirna Battles Genes Gone Bad Pharmaceutical start-up Sirna Therapeutics tests drugs to silence rogue genes. Investors, while drugs based on RNA interference may have the potential to become the next big thing in biotechnology, they're still a long, long way from becoming FDA-approved, marketable entities. |
The Motley Fool
November 14, 2008
Brian Orelli |
Gravy or Turkey From the FDA? Johnson & Johnson, Genzyme, and AstraZeneca should be made aware of their FDA fate over the next few weeks. |
Bio-IT World
December 15, 2004
Zachary Zimmerman |
Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies. |
The Motley Fool
January 31, 2011
Brian Orelli |
Time to Buy Into Stem Cells? New developments bring this analyst a step closer to opening his wallet. |
Bio-IT World
July 15, 2003
Malorye Branca |
Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain. |
The Motley Fool
September 21, 2006
Brian Lawler |
Another Partner for Biogen The pharmaceutical enlists help to thwart a troublesome illness. After the market closed yesterday, Biogen added another collaboration agreement with Alnylam Pharmaceuticals to its long list of partners. Investors, take note. |
Bio-IT World
November 2006
Kevin Davies |
Merck's $1.1 Billion Bet on RNAi As if the 2006 Nobel Prize in Medicine or Physiology wasn't validation enough, Merck's acquisition of biotech firm Sirna for $1.1 billion last month offered evidence of the commercial implications of RNA interference gene-silencing technology. |
Bio-IT World
December 15, 2004
Nancy Weil |
Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic. |
The Motley Fool
November 13, 2006
Jack Uldrich |
Arrowhead: A Long-Term RNAi Play? Its majority stake in Calando Pharmaceuticals could pay dividends. Investors would be wise to continue to watch this company and wait until clinical trials have advanced to a more mature stage before considering an investment. |
The Motley Fool
July 3, 2008
Brian Lawler |
A Cubist Masterstroke Cubist Pharmaceuticals, until now a one-drug wonder, becomes a marketer of two compounds. |
The Motley Fool
June 23, 2010
Brian Orelli |
A Novel Drug Technology Worth Watching Regulus signs up another microRNA partner. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
Pharmaceutical Executive
October 1, 2008 |
The other half of an HIV mystery is solved When HIV infects a human immune cell, which of the cell's own genes play a role? |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
The Motley Fool
November 13, 2006
Jack Uldrich |
Prepare Your Retirement for a Big Bang Investors should plan on living longer than expected. |
BusinessWeek
February 26, 2007
Gene G. Marcial |
CytRx Can 'Silence' Genes That Cause Disease Since October, shares of CytRx have more than doubled as investors zeroed in on its RNA interference technology that targets diabetes, obesity, and ALS. |
Chemistry World
June 19, 2015
Rebecca Trager |
Alnylam accuses Dicerna of stealing trade secrets The US biopharmaceutical company Alnylam has filed a 'trade secret misappropriation' lawsuit against fellow Cambridge-based firm Dicerna. |
Bio-IT World
December 15, 2004
David A. Bumcrot |
Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi. |
The Motley Fool
July 20, 2006
Brian Lawler |
Cubist's Square Results The pharmaceutical company has a promising new drug, but little else in the pipeline. Investors, take note. |
The Motley Fool
September 10, 2007
Brian Orelli |
Double Your RNA Pleasure Alnylam and ISIS join together to work on microRNAs. Their joint venture, called Regulus Therapeutics, combines their intellectual property in an effort to advance this new technology. Investors should take note. |
The Motley Fool
December 28, 2007
Brian Lawler |
Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen. |
The Motley Fool
April 21, 2009
Brian Orelli |
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. |
The Motley Fool
April 6, 2011
Brian Orelli |
Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years. |
Managed Care
November 2003
Thomas Morrow |
Making Sense of Antisense and Interference Treatments that interfere with protein synthesis at the cellular level will soon be debated in medical policy committee meetings. |
The Motley Fool
April 5, 2011
Brian Orelli |
Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva. |
The Motley Fool
May 12, 2004
Charly Travers |
Cubist Addresses a Niche Market This small firm is developing antibiotics to meet a medical need. |
Chemistry World
November 1, 2011
Sarah Houlton |
A Shot in the Arm for Drugs for Neglected Diseases A new consortium of public and private sector partners has been launched by the World Intellectual Property Organization. Its aim is to share intellectual property that may help find drugs for malaria, tuberculosis and other neglected tropical diseases. |
Bio-IT World
March 2006 |
News Blast Merck/Phase Forward... Curbing a Pandemic... Focused Trials... Collaboration... |
The Motley Fool
October 4, 2007
Billy Fisher |
Isis Keeps Cholesterol Down, Stock Prices Up Isis Pharmaceuticals reports positive phase 2 results for a cholesterol treatment. The company continues to show progress with its impressive pipeline of 17 other development-stage drugs. Investors, take note. |
The Motley Fool
September 8, 2006
Ralph Casale |
Genta's Down, but Is It Out? An FDA advisory committee voted not to recommend Genta's lead drug, Genasense, for approval. The news has knocked Genta's stock down by nearly two-thirds over the past week. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
